News Standardised Testing Regime Proposed For UK CBD Industry

Standardised Testing Regime Proposed For UK CBD Industry



FOLLOWING talks with the Home Office and food regulators, efforts are now under way to to establish a new testing regime for the CBD industry.

The Association for the Cannabinoid Industry (ACI) today announced it is pressing ahead with trials on a new protocol in conjunction with UK Government chemists and testing firm Eurofins.

Steve Moore, of the Association for the Cannabinoid Industry (ACI).

And, the initiative appears to have clarified a common mis-understanding on the levels of THC allowed in retail CBD – setting a benchmark of 1mg (milligram) per item.

Steve Moore of the ACI said in a press briefing: “We stand for an industry delivering safe and compliant products. It’s important for our members that we provide the best possible stewardship and to call out those companies who do not comply. 

“This is a vital piece of development work for the ACI – an essential step towards standardisation for the industry – which will reap its reward in the years to come.”

THC Traces At One Part Per Million

A standard analytical testing methodology for CBD product testing does not exist. This means test results can differ from laboratory to laboratory. 

After months of work the ACI has produced a set of protocols and, following rigorous scrutiny, Eurofins has found them ‘robust’.

The ACI and the Laboratory of Government Chemists (LGC) will now focus on the development of a precise cannabinoid testing methodology based on these principles. 

The High Performance Liquid Chromatography/Mass Spectrometry (HPLC/MS) technology which is being deployed can detect THC down to a level of 1PPM (one part per million), as well as detecting over a dozen additional cannabinoids.

Up to now there has been no
standard analytical methodology
for CBD product testing.

Dr Parveen Bhatarah

Dr Parveen Bhatarah, ACI Regulatory and Compliance Unit Lead, said that after undertaking an initial gap analysis it has now been able to lay the foundations for a sanctioned testing regime.

“Up to now there has been no standard analytical methodology for CBD product testing. Test result variations are further complicated due to the instability of most of these cannabinoids to light, temperature, humidity and air meaning sample preparation is key to consistency. 

“Eurofins have demonstrated our protocols to be robust and we look forward to moving this standardisation forward with LGC.”

Home Office Opens Dialogue With Industry

Mr Moore said this testing initiative follows a significant thawing in relations between the industry and the Home Office.

“The Government have been prevaricating on this for some time, but we have now got to the stage where the industry can have an elevated conversation with the Home Office and the FSA (Food Standards Agency), and that engagement has been critical.

“In the past there has always been vagueness from these bodies, but we are now submitting Novel Food dossiers. We are no longer just talking, we are doing, and in the process generating millions of pounds in food safety investment for retailers and consumers,” he said.

The issues of CBD safety and product content is a thorn in the side of regulators and consumers and was highlighted in a series of tests on 30 retail CBD products, last year.

It found discrepancies between what was stated on the label and actual contents, and many products included elevated levels of the psychoactive cannabinoid THC.

Testing To Support Novel Food Regime

There has been some confusion in the industry over acceptable THC levels in food retail products with a benchmark of 0.2%THC, or 100PPM – 1mg in a 10ml container – touted as acceptable.

However, Marc Marc Burbidge, Development & Quality Lead at the Centre for Medicinal Cannabis confirmed that the Home Office has settled on a level of 1mg per retail product.

Mr Moore added: “The industry is in unsatisfactory state. Last year’s consumer product tests demonstrated clear breaches of the basic standards expected for the consumer.

“This new initiative will act as an important part in building the infrastructure required to reassure those consumers.”

An exemplary testing and analysis process is a key requisite in securing a Novel Food authorisation. All UK CBD companies are expected to have submitted a Novel Food application by March 31, 2021.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


Please enter your comment!
Please enter your name here

Latest news

As Six-Year Legal Battle Nears End French Cannabis Pioneer Outlines Vision For Europe’s CBD Future

ONE of the French entrepreneurs locked in a six-year court battle over the legality of a...

Austrian CBD Firms And Regulators Work To Create Safe And Compliant Industry

AUSTRIAN seed-to-sale CBD firm MAGU says the future looks brighter under a new cannabis-friendly Government. Co-Founder...

Tens Of Thousands Could Benefit From Stop-Gap To Address UK Medical Cannabis Impasse

MEDICINAL cannabis prescribing could be handed over to the UK’s private clinics in a move which would...

Grow Pharma Signs Partnership Deal With Australia’s Althea – Boosting UK Medical Cannabis Range by 20%

UK MEDICAL cannabis distributor Grow Pharma has boosted its patient product range by 20% after striking a...


Market Round-Up: Aurora Cannabis, Green Thumb Industries, Curaleaf, Emmac, Materia Ventures, et al…

NORTH American cannabis sales hit record levels with Covid-19 lockdown-customers in the both the US and Canada...

Huge Stride For UK Medicinal Cannabis With £12m Plan To Cultivate 300,000 Plants A Year

PLANS have been unveiled for a £12m investment to create one of the UK’s largest medicinal cannabis...

Must read


You might also likeRELATED
Recommended to you